The biopharma landscape is shifting fast, driven by evolving pricing policies, geopolitical trade tensions, and mounting pressure to optimise R&D investment. With the recent push toward nation-based drug pricing, global companies are being forced to rethink not just pricing models, but where and how they innovate.
A candid conversation with industry experts on how these policy changes are impacting R&D pipelines, funding strategies, and outsourcing decisions.
If you’re leading R&D, shaping strategy, or navigating the evolving biotech landscape, you would not want to miss this.
